A novel anti-cancer compound synthesized by scientists at the University of California, San Diego more than a decade ago from toxins of the poisonous jack-o-lantern mushroom, has been granted “fast... Food and Drug Administration (FDA) after demonstrating promise against one of the most deadly cancers.
- Mechanism
- Curator reviewed
MGI-114(Irofulven) has unique mechanism of action as an anti-tumor agent is due to its ability to be rapidly absorbed by tumor cells. Once inside the cells, the compound binds to DNA and protein targets. This binding interferes with DNA replication and cell division of tumor cells, leading to tumor-specific apoptotic cell death, or “cell suicide.” During this process, tumor cells tend to automatically shut themselves down when they sense their function is compromised.
- Primary indication
- Investigated for use/treatment in brain cancer, breast cancer, endometrial cancer, liver cancer, lung cancer, ovarian cancer, pancreatic cancer, pediatric indications, prostate cancer, and sarcoma.Curator reviewed
- Formula / weight
- C15H18O3 · 246.3016 g/mol (avg)
- Also known as
- HMAF
- Code names
- MGI-114 · NSC-683863
Resolves to
NICJCIQSJJKZAH-AWEZNQCLSA-NSMILESCC1=C(CO)C2=C(C)C3(CC3)[C@@](C)(O)C(=O)C2=C1What you can answer from here — as of January 29, 2025
Which drugs share a target with Irofulven, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account